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Aeroallergen challenge of atopic asthmatics 
triggers an initial short-lived bronchoconstric-
tion reaction mediated predominantly by IgE-
armed mast cells, followed by a later and more 
sustained reaction associated with T helper 
(Th)2 cell activation in the airway mucosa 
(1). Indirect evidence (2) suggests that this late 
asthmatic reaction may be elicited directly 
by the products of activated allergen-reactive 
T cells. Ensuing damage to airway mucosal 
tissues during this response, in particular by 
infi  ltrating eosinophils activated via Th2 cell–
  derived cytokines such as IL-5 (1), results in 
many asthmatics in the subsequent development 
of airways hyperresponsiveness (AHR) to in-
haled irritants. The duration of AHR after asthma 
exacerbation is highly variable and is one of 
the most important determinants of disease 
severity. In the most severe forms of chronic 
asthma, AHR can develop into an essentially 
continuous state, resulting in markedly reduced 
respiratory function.
The most important aeroallergens involved 
in asthma pathogenesis are ubiquitous “indoor” 
allergens, which are present continuously in 
the airborne environment (3). This begs the 
questions of why only a relatively small subset 
of atopics sensitized to this class of allergens 
manifest wheezing symptoms and/or AHR (4), 
and why individual late phase reactions (LPRs) 
typically terminate within a few hours.
Recent reports have highlighted the poten-
tially important role of CD4+CD25+ T reg 
cells in control of T cell–mediated  infl  ammation 
(5). There are two major categories of T reg 
cells. First, the naturally occurring thymically 
derived CD4+CD25+Foxp3+ cells and,  second, 
antigen-specifi  c T reg cells, which can be in-
duced in vitro or in vivo under particular condi-
tions of antigenic stimulation. Antigen-induced 
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T reg cells include a heterogeneous mix of phenotypes and 
include Th1 and Th2 types, which produce the antiinfl  am-
matory cytokines IL-10 and/or TGF-β (5). Recent studies 
suggest that naturally occurring T reg cells and antigen-
  induced IL-10–secreting T reg cells have a role in protecting 
against human allergic disease. A mutation in the gene en-
coding Foxp3, which confers suppressive activity on T reg 
cells, results in IPEX syndrome, which involves multiple pa-
thologies including allergic symptoms (5). Additionally, the 
frequency of allergen-specifi  c IL-10–secreting T reg cells is 
reportedly reduced in atopics relative to nonatopics (6), and 
therapies benefi  cial for treatment of asthma/allergy (gluco-
corticoids and immunotherapy) have been shown to induce 
antiinfl   ammatory cytokine production by T cells and to 
modify T reg cells function (5, 7).
In animal models, several lines of indirect evidence also 
argue for a role for T reg cells in control of asthma/allergy. 
First, naturally occurring T reg cells have been shown to limit 
experimental airway infl  ammation and to modulate allergen-
driven AHR (8). A similar role has been proposed for IL-10 
and TGF-β producing adaptive T reg cells based on studies 
in mouse asthma models (9–14). However, a limitation in the 
majority of these studies has been their focus on T reg cells 
generated in vitro or at systemic lymphoid sites such as spleen, 
and as such they do not address issues relating directly to mi-
croenvironmental regulation at the site of aeroallergen chal-
lenge. A more restricted series of studies (9, 11, 12) have 
attempted to bridge this gap by focusing on T reg cell–associ-
ated cellular functions in whole lung digests or in lymph 
nodes draining the peripheral lung as surrogate models for 
events occurring at the asthma lesional site in the mucosa of 
the conducting airways. As we have reported recently (15, 
16), there are considerable diff  erences in the functional phe-
notype of cell populations involved in control of T cell acti-
vation in these diff  erent tissue compartments, which question 
the validity of such extrapolations.
This study instead focuses directly on eff  ector and regula-
tory cell populations extracted from the conducting airway 
Figure 1.  Cellular responses in the tracheal mucosa in sensitized 
animals during OVA aerosol exposure. Cell numbers as percentage of 
tracheal digest population: (A) TcRαβ+; (B) CD25+ TcRαβ+; (C) % MHC 
Class II+; (D) CD86+ AMDC. Data shown as mean ± SE for days 0–5 and 
10 inclusive (n ≥ 3 separate experiments, using pools of >10 animals 
each), or representative of at least two experiments for days 6–9. Tracheal 
digests were prepared 2 h after OVA aerosol exposure on designated day. 
After exposure > day 0: *, P < 0.05; **, P <0.01; ***, P < 0.001; 
****, P < 0.0001. (E) Gate settings used for selection of high MHC class II+ 
AMDCs (R1) in digest after macrophage and B cell depletion as per refer-
ence 15. (F–L) Staining profi  les of MHC class II versus isotype control mAb 
OX21 (F, H, and K) or CD86 (G, J, and L) surface expression on tracheal 
digest AMDC (as defi  ned in R1) after either no (F and G), a single (H and J), 
or multiple (mOVA; K and L) OVA aerosol exposures of presensitized 
  animals. Data shown are representative FACS plots from a series of at 
least three separate experiments.JEM VOL. 203, November 27, 2006  2651
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mucosa itself and its major draining lymph nodes (DLNs), 
avoiding contamination with cells from other parts of the 
lung which are not directly involved in the asthma disease 
process. We demonstrate that the restoration and subsequent 
maintenance of immunological and physiological homeosta-
sis in the airway mucosa after an experimental asthma ex-
acerbation is a dynamic allergen-driven process involving 
interplay between allergen-specifi  c Th2 cells, airway muco-
sal dendritic cells (AMDCs), and CD4+CD25+ T reg cells. 
Moreover, ongoing protection of airway tissues in sensitized 
animals via T reg cells relies absolutely on continuation of 
allergen exposure, as withdrawal of stimulation restores sus-
ceptibility to the Th2-dependent AHR-inducing eff  ects of 
aeroallergen challenge.
RESULTS
These studies used a rat model developed in our laboratory 
to study cellular events in the airway mucosa triggered by 
exposure of sensitized animals to aerosolized OVA, focusing 
in particular on the initiation phase of the T cell activation 
response after challenge. Our forerunner studies (15) have 
demonstrated that OVA aerosol exposure of sensitized rats 
leads to concomitant up-regulation of CD86 expression and 
APC activity within the AMDC compartment by 2 h after 
exposure, and is followed by local activation of Th cells and 
development of AHR to inhaled methacholine (MCh), 
which is a common feature of asthma exacerbation in hu-
mans. This experimental system was further modifi  ed in this 
study to encompass repeated (daily) OVA aerosol challenge 
to model the eff   ects of exposure of atopic asthmatics to 
aeroallergens present continuously within the airborne en-
vironment. Fig. 1 illustrates the density and phenotype of 
AMDCs and adjacent T cells in the tracheal mucosa, as-
sessed at 2 h after the fi  rst OVA-aerosol exposure of sensi-
tized animals, and ensuing responses in other animals 
exposed repeatedly for up to 10 consecutive days. As shown 
in Fig. 1, A and B, the number of TcRαβ+ cells and those 
expressing CD25 increase markedly during the fi  rst  two 
days of exposure, and remain elevated thereafter as exposure 
continues. Examination of AMDCs from the same tracheal 
samples (gating strategy shown in Fig. 1 E) revealed a quali-
tatively diff   erent response. Notably, AMDCs increased 
transiently in number within the 24 h after initiation of 
aerosol exposure, subsequently returning slowly to baseline 
(Fig. 1 C), whereas the proportion of AMDCs expressing 
CD86 increased explosively after a single exposure (Fig. 1, 
D, H, and J) as reported previously (15). However, unex-
pectedly, and in marked contrast to that seen with the T 
cells, this latter AMDC response disappeared entirely after 
24 h and could not be elicited again despite repeated exposure 
(Fig. 1, D, K, and L). Fig. 1 (F  –L) illustrates this transient 
up-regulation of CD86 on AMDCs, showing representative 
FACS plots of CD86 expression (Fig. 1, G, J, and L) and 
isotype control mAb OX21 binding (Fig. 1, F, H, and K) 
for naive control animals (Fig. 1, F and G) and for animals 
which have been sensitized and exposed to either a single 
(OVA x1; Fig. 1, H and J) or multiple (mOVA; Fig. 1, K 
and L) OVA aerosols.
We next questioned whether maintenance of resistance 
on the part of AMDCs to the CD86-inductive eff  ects of 
OVA required continuation of allergen exposure. To address 
this issue we compared groups of OVA-sensitized animals 
exposed repeatedly to cycles of multiple (5–8) OVA aerosols 
with intervening 14-d exposure-free rest periods. Fig. 2 illus-
trates data representative of this experimental series. Consis-
tent with the results in Fig. 1, the markedly up-regulated 
CD86 response in the airway mucosa preceding the initial 
LPR was shut down by repeated exposure (Fig. 2 A), whereas 
total and CD25+ T cell numbers remained elevated (Fig. 2, 
B and C). The 14-d rest period was accompanied by a de-
cline in levels of local T cells toward baseline. Rechallenge 
with OVA aerosol at the end of the rest period elicited a vig-
orous but again transient CD86 response (Fig. 2 A) equiva-
lent to that observed during the initial challenge cycle, 
accompanied again by a persistent T cell response (Fig. 2, B 
and C, and Fig. 1). In a single series of follow-up experiments 
we have also extended observations to encompass a third 
Figure 2.  Fluctuations in tracheal mucosal cellular responses 
  during repeated versus intermittent aerosol exposure. Animals were 
exposed to single (OVA × 1) versus multiple (mOVA) aerosol exposures, 
and rested for 14 d ([r14]) before a second exposure cycle. Data shown 
are representative analyses of airway mucosa (tracheal digest for groups 
of n ≥ 15) from one of two time course studies illustrating: (A) % CD86+ 
AMDCs in tracheal digest at 2 h after OVA aerosol exposure as indicated; 
(B) TCRαβ+ cells as the percentage of tracheal digest in the same prepa-
rations; (C) CD25+ TCRαβ+ cells as the percentage of tracheal digest in 
the same preparations.2652  T REG CELL CONTROL OF AIRWAY MUCOSAL DENDRITIC CELLS | Strickland et al.
post-rest exposure cycle, again demonstrating comparably 
rapid CD86 up-regulation on AMDCs at 24 h after reinitia-
tion of aerosol exposure (unpublished data).
These cellular responses in the airway mucosa were mir-
rored in the BAL (Fig. 3) by biphasic changes in total cell 
numbers (A) and in populations of BAL macrophages (B), 
lymphocytes (C) and eosinophils (D) in response to compa-
rable cycles of repeated exposure/rest/rechallenge. Serum 
OVA-specifi  c IgE titers followed the same cyclic pattern 
  (unpublished data).
As shown in Fig. 4 A, OVA-sensitized animals exhibited 
marked AHR at 24 h after the initial OVA aerosol challenge 
compared with naive controls exposed to the same OVA 
aerosol protocol, as illustrated by the reduced MCh dose re-
quired to increase airway resistance to ≥200% saline control 
(EC200). Consistent with the cellular responses, further con-
tinuation of exposure resulted in a return to baseline   levels 
of MCh responsiveness (illustrated in Fig. 4 B by the fi  rst 
mOVA group shown), inferring the onset of a form of toler-
ance. Moreover, withdrawal of exposure for 14 d restored 
sensitivity to aerosol challenge, as evidenced in this case by 
reestablishment of AHR to MCh in the second exposure cy-
cle (Fig. 4 B). In parallel with the pattern observed during the 
initial cycle of multiple OVA aerosol exposures this resur-
gence in AHR was again transient, returning to baseline levels 
when the animals were exposed to multiple OVA aerosols.
The experiments in Fig. 5 illustrate aspects of the DC 
regulatory functions of cells present in the tracheal mucosa of 
multiaerosol exposed animals, using an in vitro model devel-
oped in our early studies (15). The top panel illustrates 
changes in in vitro CD86 expression on tracheal DC in the 
presence of diff  erent cell populations from the same tissue 
site, and the bottom panel displays paired FACS plots from 
Figure 3.  BAL responses in OVA-sensitized animals during repeated 
OVA exposure and rest/challenge cycles. After the fi  rst cycle of re-
peated OVA exposures (1, 3, or multiple), animals were rested for 14 d 
([r14]) before reexposure to either a single aerosol or multiple aerosols; 
BAL was performed at the time points indicated. Cell numbers per BAL per 
animal: (A) total number of cells recovered; (B) macrophages per BAL per 
animal; (C) lymphocytes per BAL per animal; (D) eosinophils per BAL per 
animal. Data are from a sequential series and are expressed as mean ± SE 
(n = 5 per group) taken at 24 h after fi  nal OVA aerosol exposure. After 
exposure > day 0 or as indicated by adjoining lines: *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
Figure 4.  AHR to inhaled MCh. (A) AHR after exposure to aerosolized 
OVA of nonimmunized versus OVA-sensitized animals. Shown are 
  representative dose–response curves to MCh challenge measured at 24 h 
after a single OVA aerosol. Note the shift in the curve of the sensitized 
animals displaying marked AHR. OVA ×1 > naive control; *, P = 0.003 
by student’s t test. (B) EC200 Raw (the concentration of MCh required to 
double airway resistance) was determined in OVA-sensitized animals after 
one or multiple aerosol challenges as detailed in reference 15 and in 
groups of animals which had undergone the challenge/rest/rechallenge 
protocol. At each observation point, individual sets of naive animals ex-
posed to a single OVA aerosol (negative/baseline controls) and sensitized 
animals exposed to a single OVA aerosol (positive AHR controls) were 
included. Data shown are expressed relative to naive controls (mean 
EC200 4.49 ± 0.41 mg/ml). Figures represent mean (n ≥ 8 individual 
animals for each group) absolute reduction or increase in EC200 (in mg/ml 
MCh) relative to the mean control value (set at zero). OVA ×1 > mOVA, 
P, < 0.001; OVA ×1 > mOVA [r14], P = 0.021; OVA ×1 > mOVA, [r14], 
OVA ×1, P = 0.738; OVA ×1 > mOVA [r14] mOVA, P = 0.041, by ANOVA 
(Holm-Sidak after hoc test). JEM VOL. 203, November 27, 2006  2653
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selected cultures. As shown previously (15), the OVA-aerosol–
induced up-regulation of CD86 on resting AMDCs can 
be mimicked in vitro by brief co-culture of naive control 
AMDCs with OVA plus a source of OVA-specifi  c Th cells 
(Fig. 5, culture A vs. culture C), modeling the eff  ects of cog-
nate interactions between transiting memory T cells and an-
tigen-bearing resident AMDCs within the tracheal mucosa 
during the fi  rst few hours after allergen challenge. The intro-
duction into these cultures of unfractionated tracheal mucosal 
cells (culture D) or purifi  ed tracheal TcRαβ+ cells (culture J) 
from animals exposed on 8 consecutive days to OVA, mark-
edly reduced Th cell–induced CD86 up-regulation on AM-
DCs. This inhibitory activity was not present in tracheal cell 
preparations from unexposed animals (unpublished data). 
Prior depletion of the tracheal cell preparation of TCRαβ+ 
cells (culture E), CD4+ cells (culture F), or CD25+ cells (cul-
ture G) before introduction into the culture system abrogated 
this inhibitory activity, suggesting the presence of functional 
CD4+CD25+ T reg cells. Additionally, we observed that de-
pletion of MHC II+ cells from the tracheal preparation abol-
ished this regulatory activity and instead promoted the 
CD86-inductive eff  ects of OVA-specifi  c T cell–DC inter-
action (culture H). This suggested that depletion of MHC 
class II+ cells had unmasked an additional cellular source of 
CD86-inductive signals capable of driving AMDC activation/
maturation. Supporting this possibility, follow-up experi-
ments performed as per culture H but without the inclusion 
of the exogenous OVA-specifi  c Th cells demonstrated com-
parable levels of ensuing CD86 up-regulation on AMDC 
(unpublished data).
Fig. 6 (A–H) illustrates the results of quantitative RT-
PCR analyses of expression of selected marker genes in 
CD4+CD25+ cells sorted from tracheal mucosa of resting 
OVA-sensitized controls and those exposed to single or mul-
tiple OVA aerosols over two exposure cycles. Foxp3 and 
LAG-3 expression were not seen in CD4+CD25− or 
CD4−CD25− populations sorted from the same digests (un-
published data). Of note is the stepwise up-regulation in 
Figure 5.  Modulation of Th cell–induced CD86 expression on 
AMDCs by immunoregulatory cells from the tracheal mucosa. Purifi  ed 
AMDCs from naive animals were cultured alone (A) or in the presence of 
T cell–enriched OVA immune lymph node cells (C) at a density of 20:1 
(T cells to DCs). 3 h after addition of 50 μg/ml OVA, CD86 staining was 
examined and MFI and proportion of AMDCs expressing CD86 determined 
after accounting for nonspecifi  c binding of the isotype control (C versus A). 
Parallel cultures of DC/OVA-specific T cells/OVA were further supple-
mented with tracheal digest cells from sensitized animals exposed to eight 
OVA aerosols at a ratio of 1:4 (tracheal cells to DCs), either unfractionated 
(B and D) or after depletion of cells expressing TcRαβ (E), CD4 (F), IL-2R (G), 
or MHC class II (H); resulting CD86 expression at 3 h was then deter-
mined and normalized against that in the positive control culture (C). Note 
that cultures depleted of MHC class II+ cells gave identical results with/
without addition of exogenous OVA (+/−). Purifi  ed TcRαβ+ tracheal cells 
selected by multiparameter sorting (culture J) were added to other cultures 
at a ratio of 1:2 (TcRαβ+ to DCs), and resulting CD86 expression levels 
again normalized against culture C. Data shown are group means ± SE, 
except for culture J (representative of two experiments; individual group 
sizes ≥20). CD86 expression on AMDCs signifi  cantly different from culture 
C; *, P < 0.0001 by paired t test; CD86 expression signifi  cantly different 
from culture D; *, P < 0.1; **, P < 0.05; ***, P < 0.01 by paired t test.2654  T REG CELL CONTROL OF AIRWAY MUCOSAL DENDRITIC CELLS | Strickland et al.
  tracheal mucosal CD4+CD25+ of the transcriptional regulator 
Foxp3 (Fig. 6 A) which is a marker of T reg cells activity (5), 
over the course of the successive rechallenge protocols. Up-
regulation of the additional T reg cell–associated markers 
LAG3 (Fig. 6 B; reference 17) CTLA4 (Fig. 6 C; reference 
18) and IL-10 (Fig. 6 D) was also observed in the tracheal 
CD4+CD25+ population from animals exposed to multiple 
aerosols, both before and after the rest period. Levels of TGF-β 
(Fig. 6 F) remained consistently low in all groups. We addi-
tionally compared levels of expression of the Th2-trophic 
transcription factor GATA-3 and its Th1 counterpart T-bet. 
This mucosal CD4+CD25+ population was enriched for 
GATA-3–expressing cells and even higher expression was 
observed in the overall unfractionated mucosal TCRαβ+ 
population (unpublished data), indicating strong Th2 polar-
ity, refl  ecting the Th2-skewing properties of the OVA prim-
ing protocol used. Levels of T-bet were consistently low for 
all preparations examined (<20 arbitrary units; unpublished 
data). The Th2 genes typically associated with allergic air-
ways infl  ammation, IL-4, IL-5, and IL-13, were also exam-
ined. A small transient spike in expression of IL-5 (Fig. 6 G) 
and IL-13 (Fig. 6 H) was observed after a single OVA aerosol 
challenge of sensitized animals. Of note, this response was 
seen to be substantially boosted after the rest period and a 
single further OVA aerosol challenge. IL-4 expression was 
not detected in any of the preparations examined (<10 arbi-
trary units; unpublished data). Expression levels of CD127 
were also found to be consistently low (<10 arbitrary units; 
unpublished data).
Next, we identifi  ed the T reg cells in the airway mucosa 
via immunofl  uorescent staining of tracheal digest prepara-
tions, as illustrated in Fig. 7 (A    –J) by representative FACS 
plots from a series of experiments. The CD25+ gated popula-
tion (Fig. 7, A  –H) in tracheal digest preparations from sensi-
tized controls or animals sensitized and exposed to a single or 
multiple OVA aerosols are shown, depicting expression of 
CD4 and Foxp3 (Fig. 7, B, E, and H) relative to isotype con-
trols (Fig. 7, A, D, and G). Surface expression of CD4 and 
CD25 on tracheal digest cells gated for Foxp3 are shown for 
the same groups of animals (Fig. 7, C, F, and J). We also de-
termined that these Foxp3+ cells expressed surface CD45RC 
illustrative of the memory phenotype in the rat but did not 
express CD103 or CD127 (unpublished data). The total 
number of Foxp3+ cells on a per trachea basis as determined 
via intracellular staining is shown in Fig. 7 K. Of particular 
note is the large scale increase in the total number of Foxp3+ 
cells per trachea after the initial cycle of repeated OVA 
aerosol exposures compared with controls or animals having 
experienced only a single exposure. The maintenance of 
  elevated numbers of Foxp3+ cells in the airway mucosa is de-
pendent on continuing OVA aerosol exposure as animals re-
ceiving only a single aerosol returned to baseline levels over 
the subsequent 6 d (unpublished data). Moreover, after cessa-
tion of exposure of the mOVA group and the ensuing rest 
period, the number of Foxp3+ cells per trachea also returned 
to baseline levels (Fig. 7 K). It is of interest to note that de-
spite the major reduction in Foxp3+ population size in this 
group, the cells that persisted maintained elevated levels of 
Foxp3 gene expression (Fig. 6 A). A further cycle of multiple 
OVA exposures resulted in a resurgence in the numbers of 
Foxp3+ cells in the tracheal mucosa. PCR analysis of sorted 
CD4+CD25+ T reg cells from additional groups of animals 
undergoing this second cycle of challenge after resting indi-
cated that this resurgent T reg cells response was accompa-
nied by additional up-regulation of Foxp3, LAG-3, CTLA-4, 
and IL-10 expression (Fig. 6, A  –D). It is noteworthy that 
  although the numerical increase in Foxp3+ cell numbers in 
the second exposure cycle was less than that observed in 
the fi  rst cycle (Fig. 7 K), a reciprocal pattern was observed 
with respect to Foxp3 gene expression (Fig. 6 A). As noted 
already these cells express the memory phenotype, and these 
observations may collectively indicate progressive selection 
for smaller numbers of more potent T reg cells over time, but 
Figure 6.  qRT-PCR profi  ling of tracheal cells. (A–H) Data from a rep-
resentative experiment shows relative expression levels of Foxp3 (A), LAG-3 
(B), CTLA4 (C), IL-10 (D), GATA-3 (E), TGF-β (F), IL-5 (G), and IL-13 (H) genes 
in sorted CD4+CD25+ tracheal cells from groups of ≥15 OVA-primed ani-
mals exposed to 0, 1, or multiple aerosol exposures (mOVA) over successive 
exposure cycles as indicated. Data are expressed as arbitrary RT-PCR units 
derived by normalization against the housekeeping gene Eef1α1.JEM VOL. 203, November 27, 2006  2655
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additional comparative experiments will be required to test 
this possibility.
The in vitro suppressive activity of sorted CD4+CD25+ 
cells from the tracheal mucosa of animals exposed to multiple 
consecutive OVA aerosols is formally demonstrated in Fig. 7 L, 
which shows >80% suppression of the proliferative response 
of OVA-primed LN cells at T reg cells to LN ratios of 1:10 
and 1:20. In a further experiment (unpublished data), further 
titration of the CD4+CD25+ population revealed that a 1:40 
ratio of T reg cells to OVA-primed LN cells still achieved 
>50% suppression.
To gain additional insight into the nature of the in vivo 
down-regulation of AMDC activation (Fig. 1 C) by T reg 
cells induced as a result of multiple OVA aerosol exposure, 
we next sorted AMDC populations from these animals and 
determined their in vitro APC capacity, once removed from 
the suppressive milieu of the repeatedly exposed airway mucosa. 
Fig. 7 (M and N) illustrate representative proliferative 
responses of OVA-primed CD4+ T cells in the presence of 
various AMDC populations with and without the addition of 
exogenous OVA. Fig. 7 M demonstrates that with the addi-
tion of OVA to the cultures, AMDCs isolated from naive an-
imals or those previously sensitized to OVA and exposed to 
either a single or multiple OVA aerosols have comparable 
APC activity. More importantly, AMDCs derived from ani-
mals sensitized and exposed to multiple OVA aerosols were 
Figure 7.  Characterization of mucosal T reg cells. (A–J) Repre-
sentative staining profi  les of surface CD4 expression and intracellular 
Foxp3 (B, E, and H) on pooled tracheal digest preparations from groups 
of ≥15 animals gated for CD25 from control animals (A and B) and sen-
sitized animals exposed to a single (B and E) or multiple (G and H) OVA 
aerosols. Isotype controls are shown in (A, D, and G). Tracheal digest cells 
gated for Foxp3 from the same groups of animals express surface CD4 
and CD25 as illustrated in C, F, and J, respectively. (K) Total number of 
Foxp3 cells per trachea in OVA-sensitized animals during repeated OVA 
aerosol exposure/rest/reexposure cycles. Data are representative (n ≥ 2) 
experiments at each time point and derived from intracellular staining 
profiles and total digest yields after accounting for isotype control 
  staining. (L) Mean proliferative responses of LN cells obtained from 
OVA-sensitized animals in the presence or absence of CD4+CD25+ cells 
derived from the tracheal mucosa of sensitized animals exposed to mul-
tiple OVA aerosols. Data shown are from one representative experiment 
CD4+CD25+ were added at ratios of 1:10 (LN to CD4+CD25+, shaded 
bars) and 1:20 (checked bars). Addition of CD4+CD25+ cells from unex-
posed controls (1:10) was without effect (not shown). (M) Proliferative 
responses of LN CD4+ T cells from OVA/CFA-sensitized animals in the 
presence of OVA (50 μg/ml) and DCs sorted from tracheal digest of naive 
animals (■) or animals sensitized and exposed to a single (○) or multi-
ple (●) OVA aerosols. Proliferation is shown as mean CPM of triplicate 
cultures and is representative of at least two individual experiments. 
(N) Proliferative responses of LN CD4+ T cells from OVA/CFA-sensitized 
animals in the presence of AMDCs sorted from animals sensitized and 
exposed to multiple OVA aerosol (no additional OVA added to culture). 
Proliferation in L, M, and N is shown as mean CPM of triplicate cul-
tures and is representative of two or three experiments in each case. 
*, P < 0.001; **, P < 0.0005.2656  T REG CELL CONTROL OF AIRWAY MUCOSAL DENDRITIC CELLS | Strickland et al.
capable of driving an OVA-specifi  c proliferation without the 
addition of OVA to the cultures. This fi  nding mirrors our 
original report on the T memory cell–stimulating activity of 
AMDCs harvested from OVA- sensitized animals after a sin-
gle OVA aerosol exposure (15).
Finally, we addressed questions relating to the presence 
and characteristics of T reg cells in the airway DLN. The 
gene expression profi  les of CD4+CD25+ cells derived from 
DLN of controls (sensitized only), and animals sensitized and 
exposed to a single or multiple OVA aerosols, is shown in 
Fig. 8 (A  –C). As in tracheal CD4+CD25+ populations (Fig. 
6 A) Foxp3 expression in DLN CD4+CD25+ cells (Fig. 8 A) 
remained relatively consistent during this initial cycle of ex-
posure, whereas other T reg cells markers LAG-3 (Fig. 8 B) 
and IL-10 (Fig. 8 C) were unequivocally elevated as a conse-
quence of multiple OVA aerosol challenge. TGF-β expres-
sion in this cell population was minimal and independent of 
the number of OVA aerosol exposures (unpublished data) 
consistent with the pattern in CD4+CD25+ cells from the 
airway mucosa (Fig. 6 F). GATA-3 expression, but not T-
bet, was again elevated in all samples (unpublished data) as 
per the airway mucosa, whereas Th2 cytokine expression 
(IL-4, IL-5, and IL-13) was not detected. The in vitro sup-
pressive activity of CD4+CD25+ cells sorted from the DLN 
is demonstrated in Fig. 8 D. In particular, DLN cells from 
mOVA animals achieve close to complete suppression of Th 
cell proliferation at a 1:20 ratio. Characteristic staining pro-
fi  les of DLN cell preparations derived from animals sensitized 
to OVA and exposed to multiple OVA aerosols are shown in 
Fig. 8 (E–M). Relevant Foxp3 expression data for total DLN 
is shown in Fig. 8 (E and F). Gates used to defi  ne populations 
of CD4+CD25+ and CD4+CD25− populations within the 
total DLN population are illustrated in Fig. 8 (G and H). 
Foxp3 expression versus isotype control for the CD4+CD25+ 
population is shown in Fig. 8 (J and K) and Fig. 8 (L and M) 
for the CD4+CD25− population. Note the predominant lo-
calization of Foxp3 expression in the CD4+CD25+ popula-
tion. These two populations of cells were sorted from airway 
DLN of other animals exposed to multiple OVA aerosols and 
adoptively transferred into sensitized animals. 24 h after aero-
sol exposure of the recipients’ airways, responsiveness to 
MCh was determined and compared with that of aerosol-ex-
posed sensitized and naive animals (Fig. 8 N). CD4+CD25+ 
T reg cells derived from the mOVA group protected against 
Figure 8.  T reg cell–mediated changes in AHR. (A–C) Data from a 
representative experiment using group sizes of n = 5 showing relative 
gene expression levels of Foxp3 (A), LAG-3 (B), and IL-10 (C) in sorted 
CD4+CD25+ cells from airway DLNs of sensitized animals exposed to 0, 1, 
or multiple OVA aerosols as indicated. Data are expressed as arbitrary 
RT-PCR units derived by normalization against the housekeeping gene 
Eef1α1. (D) Proliferative responses of OVA-primed LN cells obtained 
from OVA/CFA-sensitized animals in the presence of CD4+CD25+ cells 
isolated from airway DLN preparations of sensitized animals exposed 
to a single (dotted bars), or multiple (shaded bars) OVA aerosols. 
CD4+CD25+ cells were added at ratios (CD4+CD25+ to LN cells) of 
1:20. Proliferation is shown as mean CPM from triplicate cultures. Addition 
of CD4+CD25+ cells from unexposed controls was without effect 
(not shown). Data are representative of three separate experiments. 
*, P < 0.05; **, P < 0.01. (E–M) Representative staining profi  les for rat G2a 
isotype control (E) and Foxp3 (F) expression in airway DLN digest prepara-
tions from animals sensitized and exposed to multiple OVA aerosols. 
CD4 versus CD25 profi  les of same DLN preparations (G and H) depict 
CD4+CD25+ and CD4+CD25− populations of cells. Staining profi  les of 
ratG2a isotype controls and Foxp3 for CD4+CD25+ cells (J and K, re-
spectively) and CD4+CD25− cells (L and M, respectively) are also shown. 
(N) EC200 was determined in OVA-sensitized animals after adoptive 
transfer of CD4+CD25+ or CD4+CD25neg cells sorted from pooled airway 
DLN of groups of ≥5 animals sensitized to OVA and exposed to multiple 
OVA aerosols or control animals (no adoptive transfer) and naive ani-
mals, on four different occasions. Data are expressed relative to naive 
controls. Figures represent mean absolute reduction or increase in 
EC200 (in mg/ml MCh) relative to the mean control value (set at zero). 
OVA ×1 > OVA ×1 + mOVA CD4+CD25+; P = 0.005; OVA ×1 > 
CD4+CD25neg, P = 0.873.JEM VOL. 203, November 27, 2006  2657
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development of AHR induced in sensitized animals by a sin-
gle OVA aerosol challenge (Fig. 8 N), reproducing the eff  ects 
observed with multiple OVA aerosol exposures (Fig. 4).
D  I  S  C  U  S  S  I  O  N 
The LPR in asthma is associated with the local activation of 
allergen-specifi  c Th2 memory cells in the airway mucosa. 
We have previously identifi  ed networks of DCs within the 
conducting airway epithelium and underlying submucosa 
of humans (19) and experimental animals (20), and as the 
sole professional APC population resident in these tissues, 
AMDCs are ideally positioned to drive activation of the 
Th2 cells, which are associated with the LPR compo-
nent of asthma exacerbations. However, in the resting state 
these AMDCs are functionally immature, being special-
ized only for uptake and processing of antigen but lacking 
  capacity for effi   cient presentation (21), thus questioning how 
allergen-specifi  c T cells are initially activated in situ during 
an asthma attack.
Our recent studies (15) have provided a plausible mecha-
nism for this T cell activation process, by demonstrating a 
sequence of cellular interactions which occur in situ within 
the airway mucosa during the fi  rst few hours after challenge 
of sensitized animals with aerosolized allergen. The crucial 
observation in these studies was the demonstration that resi-
dent AMDCs are in virtually continuous communication 
(via short-term clustering) with Th memory cells transiting 
through the airway mucosa. We demonstrated that when 
AMDCs from aerosol-exposed animals acquire antigen of 
equivalent specifi  city to (some of) these transiting T cells, the 
ensuing cognate interactions between these two cell pop-
ulations trigger CD86 expression on AMDCs and accom-
panying up-regulation of the full range of APC functions. 
This in turn stimulates their mobilization and emigration 
to DLN over the ensuing 12–24 h, during which further 
  interactions occur within the mucosa with other incom-
ing Th memory cells, resulting in their activation in situ, 
and thus in development of AHR (15, 22). This emigra-
tion process, which involves translocation of all detectable 
allergen-bearing AMDCs with APC activity to the draining 
lymph nodes within 24 h of the exposure event, eff  ectively 
terminates the response. It is likely that costimulator mol-
ecules in addition to CD86 are also directly involved in this 
process. We have previously shown that CD80 is not part of 
this response (15), but follow-up studies will be required to 
examine other possibilities.
In the present study we have further adapted this model 
to study the sequelae of a more realistic mode of allergen 
challenge which mimics that confronting human atopic asth-
matics, i.e., exposure to perennial aeroallergen which occurs 
not as a single pulse but instead on a daily basis. A key feature 
of the model is initial sensitization of animals in a manner 
to  selectively prime recirculating Th2-polarized memory 
cells, analogous to those observed in the circulation and 
the airway mucosa of human atopic asthmatics. The domi-
nance of expression of GATA-3 in the airway mucosal T cell 
population of these animals attests to the eff  ectiveness of this 
priming protocol.
The salient fi  ndings from this study are that after the trig-
gering of an initial round of AMDC activation and a subse-
quent burst of local Th cell activation, exposed animals 
rapidly become refractory to further aeroallergen exposure. 
In particular, a second round of OVA aerosol exposure as 
early as 24 h after the initial (day 1) aerosol exposure does 
not elicit an ensuing burst of CD86 expression on AMDCs. 
This “desensitized” state is maintained in the face of at least 
10 consecutive daily aerosol challenges and is paralleled by 
decreased Th2 cytokine gene expression and airways’ eosin-
ophilia, and waning of AHR which returns to baseline be-
yond day 3. Our earlier experiments (15) indicated that 
AMDCs, which acquired OVA during the initial aerosol ex-
posure and emigrated from the airway mucosa by the 24-h 
time point, are replaced in the mucosa by incoming imma-
ture DC precursors. The failure of the latter to respond (by 
CD86 up-regulation) to the second round of OVA aerosol 
exposure suggests that either the airway mucosal OVA-
  specifi  c Th2 memory cell population in these animals had 
become anergized, or that a down-regulatory control mech-
anism which prevents AMDCs responding to activation 
signal(s) from CD4+ Th2 memory cells had been triggered 
within the mucosa.
The experiments in Fig. 5 addressed these two possibili-
ties. Importantly, they demonstrate that OVA-specifi  c  T 
cell–induced up-regulation of CD86 expression on AMDCs 
can be inhibited by a population of cells which appear in the 
tracheal mucosa of OVA-sensitized animals after repeated 
aerosol exposure. The depletion experiments in this series 
(Fig. 5, F and G) identify these inhibitory cells as TcRαβ+, 
CD4+, and CD25+, and follow-up experiments extend this 
phenotype to include expression of (inter alia) Foxp3 (Fig. 7 K), 
LAG3 (Fig. 6 B), IL-10 (Fig. 6 D), and CTLA4 (Fig. 6 C), 
as well as Th cell suppressive activity in a standard lympho-
proliferation assay (Fig. 7 L), properties which are collectively 
suggestive of T reg cells. Expression of the LAG3 and IL-10 
markers in CD4+CD25+ cells in the airway mucosa display 
a particularly strong association with repeated aerosol expo-
sures, and this pattern was reiterated in the local DLN (Fig. 
7, B and C). T reg cells activity developed in parallel at this 
regional lymphoid site over a similar time frame to that ob-
served in the airway mucosa (Fig. 8 D), possibly in response 
to incoming OVA-bearing DCs which we have shown pre-
viously in this model to rapidly translocate from the tracheal 
mucosa to DLN after aerosol challenge (15).
These fi  ndings are consistent with other in vitro and in 
vivo studies demonstrating that T reg cells can modify DC to 
down-regulate expression of costimulatory molecules (8, 23), 
and with recent imaging studies showing that T reg cells can 
directly interfere with Th cell–DC interactions (24). How-
ever, they do not provide a direct link with the physiological 
in vivo endpoint of the T cell–dependent experimental LPR, 
i.e., the development of AHR. This latter issue was addressed 
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demonstrate that adoptive transfer of CD4+CD25+ DLN 
cells (of which 73% were Foxp3+) from repeatedly exposed 
animals into sensitized animals before their fi  rst aerosol chal-
lenge, is capable of abrogating ensuing AHR development.
An additional aspect of our in vitro DC activation model 
was the experiments involving selective depletion of MHC 
class II+ cells from the tracheal preparation before their addi-
tion to the cultures, which resulted in striking enhancement 
of CD86 up-regulation on the AMDCs. Moreover, compa-
rable levels of CD86 expression on AMDCs were achieved 
when the only source of OVA-specifi  c T cells in these cul-
tures were those present in the tracheal preparation itself. 
This suggests that MHC class II depletion removes residual T 
reg cells activity which had survived depletion of CD4+ or 
CD25+ cells, thus unmasking the activity of endogenous 
OVA-specifi  c Th cells in the tracheal population. It is feasible 
that the latter T reg cells may themselves express MHC class 
II (as is the case for activated Th cells in the rat; [25]). Alter-
natively, they may have been clustered with MHC class II+ 
AMDCs during the depletion process. In this context, we 
have previously demonstrated by confocal microscopy that in 
resting airway mucosal tissues, ≥65% of local Th cells are in 
intimate contact with local AMDCs, and this clustering pro-
cess is further enhanced after local antigen stimulation (15). It 
is pertinent to note that active T reg cells–DC clustering has 
recently been reported in a lymph node explant model, and 
moreover was demonstrated to inhibit ensuing activation of 
Th cells present in the same microenvironment (26).
A key additional feature of our present data is the estab-
lishment of a link between the waning of the T reg cells re-
sponse after withdrawal of the stimulatory (aerosolized) antigen, 
and the resurgence of sensitivity to a subsequent round 
of aerosol challenge. Thus, by the end of the 2-wk antigen-
fee rest period, putative T reg cell levels in the tracheal mu-
cosa had declined >10-fold to baseline levels (Fig. 7 K), 
and rechallenge with OVA aerosol at this time triggered rapid 
resurgence of Th cell–dependent CD86 expression on AM-
DCs (Fig. 2 A), accompanied by accumulation over the en-
suing 24 h of a second wave of CD25+ T cells (Fig. 2 D) and 
eosinophils (Fig. 3 D) and the reemergence of AHR (Fig. 4). 
This pattern appears repeatable for at least a third cycle, and 
possibly beyond.
Collectively, these data provide “Koch’s postulates” 
equivalent evidence that immunological and physiological 
homeostasis in the airway mucosa of sensitized animals is 
maintained in the face of chronic local antigen exposure via 
establishment of a state of dynamic equilibrium between T 
reg cells and specifi  c Th cells resulting in functional silencing 
of the Th cells, and prevention of recurrence of repeated cy-
cles of T cell activation in the airway mucosa and associated 
induction of AHR. Of note, we have demonstrated that the 
maintenance of this stable state is dependent on continuing 
allergen exposure, as T reg cells activity wanes after tempo-
rary removal of the antigen stimulus, rendering the animals 
again susceptible to another Th cell activation cycle once 
  allergen exposure is reinstituted. Such a scenario provides a 
plausible explanation for the intermittent pattern of asthma 
exacerbations typical of human atopic asthmatics.
It is additionally noteworthy that during this T reg cell–
controlled steady-state, the expression levels of GATA-3 
within the tracheal Th cell population remain high, con-
sistent with the maintenance (or possibly expansion) of 
Th2-polarised memory cells driven by the repeated allergen 
exposures. This suggests that translocation of aerosol-derived 
allergen to draining lymph nodes and/or central lymphoid 
organs where Th memory cells expansion is regulated may 
continue independently of events occurring at the challenge 
site. The maintenance of OVA-specifi  c Th2 memory cells 
during this process infers that these aeroallergen-derived 
signals emanating from the airway mucosa of chronically 
exposed animals continue to be immunogenic as opposed 
to tolerogenic, which superfi  cially appears to confl  ict with 
reports implicating Foxp3+ CD4+ CD25+ T reg cells in the 
generation of immunological tolerance to inhaled antigen 
(27, 28). Our laboratory was the fi  rst to describe this respi-
ratory tract tolerance process in relation to control of IgE 
responses to inhaled allergen (29), and demonstrated con-
tributions from a variety of T cell populations with regula-
tory properties (30–32). However, a hallmark feature of this 
tolerance process is that it can only be induced in immuno-
logically naive animals—once CD4+ Th cell priming has 
been instituted, recirculating Th memory cells are resistant 
to deletion via these forms of T cell regulation and ongoing 
aerosol exposure instead slowly expands this memory pop-
ulation (33). Our present fi  ndings are consistent with this 
conclusion but additionally emphasize that T reg cell activity 
plays a key role in prevention of tissue damage via reactiva-
tion of eff  ector–Th memory cells at challenge sites in the 
respiratory tract.
The fi  ndings reported here have important theoretical 
implications in relation to design of immunotherapeutic 
strategies for long-term control of atopic asthma, as they 
emphasize the importance of both the clonal expansion of 
  allergen-specifi  c Th cells within the central lymphoid com-
partment, and their reactivation within the airway mucosa, as 
independently regulated processes and by inference as sepa-
rate drug targets.
MATERIALS AND METHODS
Animals and allergen exposures. PVG rats were bred and maintained 
specifi  c pathogen free using techniques approved by our institutional Animal 
Ethics Committee. Randomly selected animals of both sexes aged 8–13 wk 
were used. Presensitization of animals to OVA was achieved by i.p. immu-
nization with 100 μg OVA in an alum mucaine suspension 14 d before use 
in challenge experiments. Generation of OVA-primed inguinal LN T cells 
for in vitro use was by s.c. injection with 100 μg OVA in Complete Freunds 
adjuvant. OVA aerosol challenge (using preselected LPS-low OVA [Sigma-
Aldrich]) was performed over a 60-min period (15, 33).
Media and reagents. Tissue culture medium and isolation reagents for 
preparation of airway mucosal and lymphoid tissue cells were as described 
(15, 33). All mAbs and immunostaining reagents (BD Biosciences) used for 
fl  ow cytometry have been previously described (15, 33). For intracellular 
staining of Foxp3, an anti–mouse/rat Foxp3-FLR staining kit (eBioscience) JEM VOL. 203, November 27, 2006  2659
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was used as described by the manufacturer. Immunophenotypic analysis was 
performed using a FACSCalibur fl  ow cytometer (BD Immunocytometry 
Systems) and analyzed using Flowjo software (version 4.6.1, Tree Star Inc.).
Cell preparation and culture. BAL cells were obtained by standard meth-
ods and stained using Diff   Quik (Lab Aids Pty Ltd). For airway mucosal cell 
preparation, isolated trachea were fl  ushed with PBS, cut fi  nely transversely, 
and minced with scissors. Tissue digestion and subsequent preparation of 
mononuclear cells, and selective depletion of macrophages and B cells was 
performed using methodology described in detail in forerunner publications 
(15, 33). DCs were fi  nally isolated by immunostaining the remaining cells 
with FITC-conjugated anti–rat MHC class II (OX 6 FITC; BD Biosci-
ences), which were then sorted using a Coulter EPICS Elite ESP, routinely 
to > 94% purity on the basis of morphology and staining characteristics. 
Contaminating cells were mainly CD3+ T cells or cytokeratin-positive cells, 
both <3%. Isolation of CD4+CD25+ cell populations was achieved by fi  rst 
enriching for CD25+-expressing cells using an autoMACS separator system 
based on positive selection (posseld) of labeled cells as per manufacturer’s in-
structions (Miltenyi Biotech). CD25+-enriched cells were immunostained 
with PE-conjugated anti–rat CD4 (OX35PE; BD Bioscience), and 
CD4+CD25+ cells were sorted to >96% purity. For isolation of CD4+CD25− 
cells, the fi  rst enrichment step using the autoMACS separator system was for 
CD4+ cells. CD4-enriched cells were immunostained with biotinylated 
anti–rat CD25 (OX39bio; BD Biosciences) followed by streptavidin CyC 
(BD Biosciences), and CD4+CD25− cells were sorted using a Coulter 
EPICS Elite ESP, routinely to >93%.
Determination of APC in vitro activity. Presentation of OVA by puri-
fi  ed DCs used standard techniques described previously (15, 33). In brief, 
DCs were cultured together with CD4+-enriched inguinal LN preparations 
from OVA-immunized animals. CD4+ LN T cells were cultured at 1 × 105 
per well in RPMI-5% FCS plus DC added at ratios indicated and OVA 
added at 50 μg/ml fi  nal concentration (if required) in a total volume of 200 
μl for 48 h, and then pulsed with 3H-thymidine for a further 18 h. Cell pro-
liferation was determined as mean counts per minute (CPM).
In vitro suppression assay. OVA-primed LN cells were cultured at 105 
per well in RPMI-5% FCS, with CD4+CD25+ cells added at ratios speci-
fi  ed. OVA was added at 50 μg/ml fi  nal concentration, and the cultures in-
cubated for 48 h, then pulsed with 3H-thymidine for a further 18 h. Cell 
proliferation was determined as mean CPM.
DC–T cell coculture. In DC–T cell coculture experiments, tracheal di-
gests prepared from animals exposed multiple times to OVA aerosols were 
depleted of various cell phenotypes using standard Dynabead depletion pro-
tocols as per manufacturer’s instructions. CD4+ T cells from draining lymph 
nodes were prepared as described here and in reference 15.
Adoptive transfer experiments. In adoptive transfer experiments, 1 × 
106 CD4+CD25+ or CD4+CD25− cells sorted from the DLN after multiple 
OVA aerosols were injected i.v. into sensitized animals. The next day (18 h 
after injection) recipients were exposed to OVA aerosol. Responsiveness to 
inhaled MCh was measured at 24 h after aerosol. Because of limitations in 
attainable numbers of CD4+CD25+ cells for the adoptive transfers, on any 
given day recipients were limited to two per experiment. Each experiment 
also included AHR measurements made on naive controls and sensitized/
exposed to OVA aerosol to enable direct comparisons to be made between 
all groups.
Lung function and MCh hyperresponsiveness. The techniques used 
were as described previously (15, 34). In brief, respiratory impedance (Zrs) 
was measured by forced oscillation between 0.5 and 20 Hz using a com-
puter-controlled piston ventilator. The constant–phase model was fi  tted to 
give estimates of airway and tissue mechanics (unpublished data). After base-
line lung function, MCh challenge was performed by delivering aerosols 
(2 min) of saline (control) and MCh (0.1, 0.3, 1.0, 3.0, 10.0, 30.0 mg/ml) 
during tidal ventilation. Five measurements of Zrs were made after each dose 
and peak responses reported.
RT-PCR. Total RNA was isolated from cells using RNeasy Mini kit and 
QIAshredder (Qiagen) and DNase treated using Turbo DNA-free kits 
  (Ambion). Reverse transcription was performed using Omniscript RT kit 
(Qiagen). Total cDNA was then used as template in real-time PCR using 
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) for 
40 cycles of 15 s at 95°C and 1 min at 60°C. Primer pairs for PCR were de-
signed in house. The PCR reaction contained Quantitect SYBR Green 
Master Mix (Qiagen) and 300 nM of each primer. Copy numbers of the am-
plicons were determined using standard curves generated with 10-fold serial 
dilutions of the respective standards and normalized against the reference 
Eef1α-1 gene.
Statistics. The experiments were performed using single animals (AHR 
studies, BAL studies, and IgE) or pooled tissue from 5–20 animals that were 
repeated two to fi  ve times as indicated. Unless indicated, unpaired Student’s 
t test was performed. Data is shown as mean ± SE or SD as indicated.
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